EGFR and hepatocellular carcinoma: According to Liu et al. [48], in HCC cells, the epidermal growth factor receptor (EGFR)–p38 MAPK axis increases the expression of programmed death-ligand 1 (PD-L1) via miR-675-5p and decreases the expression of human leukocyte antigen class-I (HLA-ABC) via hexokinase-2 (HK2).